{"transactions":[{"id":903713,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2026-02-18T02:14:34.000Z","date":"2026-02-10","kind":"purchase","planned":false,"acquired":true,"shares":4000000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares and warrants were purchased by the reporting person in the Issuer's follow-on offering pursuant to a prospectus supplement dated February 6, 2026, which closed on February 10, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The combined purchase price in the Offering per share of Common Stock and accompanying warrant was $0.50."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The warrants will expire on the earlier of (i) February 10, 2031 or (ii) the 180th calendar day following the public release by the Company of clinical trial data from the first cohort of the Phase 1 study of ERNA-101."}],"balance_after":4000000,"derivative":{"exercise_price":0.68,"exercise_date":"2026-02-10","underlying":"Common Stock","underlying_shares":4000000},"source":{"system":"sec-edgar","filing":"0001104659-26-016680","document":"tm265959-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/748592/000110465926016680/tm265959-2_4seq1.xml","form_type":"4"}},{"id":903712,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-18T02:14:34.000Z","date":"2026-02-10","kind":"purchase","planned":false,"acquired":true,"shares":4000000,"price":0.5,"value":2000000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares and warrants were purchased by the reporting person in the Issuer's follow-on offering pursuant to a prospectus supplement dated February 6, 2026, which closed on February 10, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The combined purchase price in the Offering per share of Common Stock and accompanying warrant was $0.50."}],"balance_after":6779440,"source":{"system":"sec-edgar","filing":"0001104659-26-016680","document":"tm265959-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/748592/000110465926016680/tm265959-2_4seq1.xml","form_type":"4"}},{"id":1115796,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-12T00:34:12.000Z","date":"2025-06-09","kind":"purchase","planned":false,"acquired":true,"shares":21241163,"price":0.1046,"value":2221825.6498,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On June 9, 2025, pursuant to a private placement offering by the Issuer and following the receipt of stockholder approval, the reporting person acquired 21,241,163 shares of the Issuer's Common Stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On June 2, 2025, the Issuer paid a dividend to all holders of record of its Series A Preferred Stock on such date of $0.05 per share of Series A Preferred Stock.  Pursuant to the terms of the Series A Preferred Stock, the Issuer elected to pay the dividend in an equivalent amount of Common Stock. As a result, the Reporting Person received 16,978 shares of the Issuer's Common Stock."}],"balance_after":41659743,"source":{"system":"sec-edgar","filing":"0001104659-25-058644","document":"tm2517798-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/748592/000110465925058644/tm2517798-2_4seq1.xml","form_type":"4"}},{"id":1156911,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (right to buy)","published_at":"2025-05-07T15:48:22.000Z","date":"2024-09-24","kind":"sale","planned":false,"acquired":false,"shares":3125976,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On November 5, 2024, the Reporting Person filed a Form 4 that included an incorrect transaction date of October 29, 2024 for the Exchange Transactions (as defined below) based on the fact that under the Exchange Agreement (as defined below) consummation of the Exchange Transactions was conditioned upon Stockholder Approval (as defined in the Exchange Agreement). This amendment is being filed to reflect the correct transaction date for the Exchange Transactions of September 24, 2024 based on the analysis set forth in footnote 2 below."},{"field":"date","element":"transactionDate","label":"F2","text":"Upon review of the relevant facts and caselaw, the Reporting Person has determined that the Stockholder Approval was not a material condition for the Exchange Transactions as the Reporting Person and several other stockholders exchanging securities with the Company had entered into support agreements with the Issuer on September 24, 2024 (as disclosed in the Issuer's Current Report on Form 8-K filed with the SEC on September 25, 2024) pursuant to which each stockholder agreed to vote all of their eligible voting securities in favor of the Stockholder Approval. According to the Issuer's Definitive Proxy Statement filed with the SEC on October 7, 2024, the parties to the support agreements owned approximately 48% of the Issuer's outstanding Common Stock, which meant that the satisfaction of the condition was practically assured and the Reporting Person became irrevocably committed to the Exchange Transactions on September 24, 2024 after all parties entered into the support agreements."},{"field":"date","element":"transactionDate","label":"F3","text":"The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the \"Exchange Agreement\"), pursuant to which the reporting person agreed to exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share (\"Common Stock\") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number) (the \"Warrant Exchange\")."},{"field":"date","element":"transactionDate","label":"F5","text":"Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval, which occurred on October 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the \"Exchange Agreement\"), pursuant to which the reporting person agreed to exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share (\"Common Stock\") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number) (the \"Warrant Exchange\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval, which occurred on October 29, 2024."}],"balance_after":0,"derivative":{"exercise_price":1.43,"exercise_date":"2023-12-15","expiration_date":"2028-12-15","underlying":"Common Stock","underlying_shares":3125976},"source":{"system":"sec-edgar","filing":"0001104659-25-045416","document":"tm2514116-1_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/748592/000110465925045416/tm2514116-1_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-11-05"}},{"id":1156910,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (right to buy)","published_at":"2025-05-07T15:48:22.000Z","date":"2024-09-24","kind":"sale","planned":false,"acquired":false,"shares":2475524,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On November 5, 2024, the Reporting Person filed a Form 4 that included an incorrect transaction date of October 29, 2024 for the Exchange Transactions (as defined below) based on the fact that under the Exchange Agreement (as defined below) consummation of the Exchange Transactions was conditioned upon Stockholder Approval (as defined in the Exchange Agreement). This amendment is being filed to reflect the correct transaction date for the Exchange Transactions of September 24, 2024 based on the analysis set forth in footnote 2 below."},{"field":"date","element":"transactionDate","label":"F2","text":"Upon review of the relevant facts and caselaw, the Reporting Person has determined that the Stockholder Approval was not a material condition for the Exchange Transactions as the Reporting Person and several other stockholders exchanging securities with the Company had entered into support agreements with the Issuer on September 24, 2024 (as disclosed in the Issuer's Current Report on Form 8-K filed with the SEC on September 25, 2024) pursuant to which each stockholder agreed to vote all of their eligible voting securities in favor of the Stockholder Approval. According to the Issuer's Definitive Proxy Statement filed with the SEC on October 7, 2024, the parties to the support agreements owned approximately 48% of the Issuer's outstanding Common Stock, which meant that the satisfaction of the condition was practically assured and the Reporting Person became irrevocably committed to the Exchange Transactions on September 24, 2024 after all parties entered into the support agreements."},{"field":"date","element":"transactionDate","label":"F3","text":"The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the \"Exchange Agreement\"), pursuant to which the reporting person agreed to exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share (\"Common Stock\") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number) (the \"Warrant Exchange\")."},{"field":"date","element":"transactionDate","label":"F5","text":"Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval, which occurred on October 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the \"Exchange Agreement\"), pursuant to which the reporting person agreed to exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share (\"Common Stock\") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number) (the \"Warrant Exchange\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval, which occurred on October 29, 2024."}],"balance_after":0,"derivative":{"exercise_price":1.43,"exercise_date":"2023-12-14","expiration_date":"2028-07-14","underlying":"Common Stock","underlying_shares":2475524},"source":{"system":"sec-edgar","filing":"0001104659-25-045416","document":"tm2514116-1_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/748592/000110465925045416/tm2514116-1_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-11-05"}},{"id":1156909,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (right to buy)","published_at":"2025-05-07T15:48:22.000Z","date":"2024-09-24","kind":"sale","planned":false,"acquired":false,"shares":523512,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On November 5, 2024, the Reporting Person filed a Form 4 that included an incorrect transaction date of October 29, 2024 for the Exchange Transactions (as defined below) based on the fact that under the Exchange Agreement (as defined below) consummation of the Exchange Transactions was conditioned upon Stockholder Approval (as defined in the Exchange Agreement). This amendment is being filed to reflect the correct transaction date for the Exchange Transactions of September 24, 2024 based on the analysis set forth in footnote 2 below."},{"field":"date","element":"transactionDate","label":"F2","text":"Upon review of the relevant facts and caselaw, the Reporting Person has determined that the Stockholder Approval was not a material condition for the Exchange Transactions as the Reporting Person and several other stockholders exchanging securities with the Company had entered into support agreements with the Issuer on September 24, 2024 (as disclosed in the Issuer's Current Report on Form 8-K filed with the SEC on September 25, 2024) pursuant to which each stockholder agreed to vote all of their eligible voting securities in favor of the Stockholder Approval. According to the Issuer's Definitive Proxy Statement filed with the SEC on October 7, 2024, the parties to the support agreements owned approximately 48% of the Issuer's outstanding Common Stock, which meant that the satisfaction of the condition was practically assured and the Reporting Person became irrevocably committed to the Exchange Transactions on September 24, 2024 after all parties entered into the support agreements."},{"field":"date","element":"transactionDate","label":"F3","text":"The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the \"Exchange Agreement\"), pursuant to which the reporting person agreed to exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share (\"Common Stock\") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number) (the \"Warrant Exchange\")."},{"field":"date","element":"transactionDate","label":"F5","text":"Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval, which occurred on October 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the \"Exchange Agreement\"), pursuant to which the reporting person agreed to exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share (\"Common Stock\") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number) (the \"Warrant Exchange\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval, which occurred on October 29, 2024."}],"balance_after":0,"derivative":{"exercise_price":1.43,"exercise_date":"2023-12-14","expiration_date":"2028-06-02","underlying":"Common Stock","underlying_shares":523512},"source":{"system":"sec-edgar","filing":"0001104659-25-045416","document":"tm2514116-1_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/748592/000110465925045416/tm2514116-1_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-11-05"}},{"id":1156908,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"6.0% Senior Convertible Promissory Notes due 2028","published_at":"2025-05-07T15:48:22.000Z","date":"2024-09-24","kind":"sale","planned":false,"acquired":false,"reported_value":3540000,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On November 5, 2024, the Reporting Person filed a Form 4 that included an incorrect transaction date of October 29, 2024 for the Exchange Transactions (as defined below) based on the fact that under the Exchange Agreement (as defined below) consummation of the Exchange Transactions was conditioned upon Stockholder Approval (as defined in the Exchange Agreement). This amendment is being filed to reflect the correct transaction date for the Exchange Transactions of September 24, 2024 based on the analysis set forth in footnote 2 below."},{"field":"date","element":"transactionDate","label":"F2","text":"Upon review of the relevant facts and caselaw, the Reporting Person has determined that the Stockholder Approval was not a material condition for the Exchange Transactions as the Reporting Person and several other stockholders exchanging securities with the Company had entered into support agreements with the Issuer on September 24, 2024 (as disclosed in the Issuer's Current Report on Form 8-K filed with the SEC on September 25, 2024) pursuant to which each stockholder agreed to vote all of their eligible voting securities in favor of the Stockholder Approval. According to the Issuer's Definitive Proxy Statement filed with the SEC on October 7, 2024, the parties to the support agreements owned approximately 48% of the Issuer's outstanding Common Stock, which meant that the satisfaction of the condition was practically assured and the Reporting Person became irrevocably committed to the Exchange Transactions on September 24, 2024 after all parties entered into the support agreements."},{"field":"date","element":"transactionDate","label":"F4","text":"The Reporting Person also agreed pursuant to the Exchange Agreement to exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collectively with the Warrant Exchange, the \"Exchange Transactions\")."},{"field":"date","element":"transactionDate","label":"F5","text":"Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval, which occurred on October 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Reporting Person also agreed pursuant to the Exchange Agreement to exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collectively with the Warrant Exchange, the \"Exchange Transactions\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval, which occurred on October 29, 2024."}],"balance_after":0,"derivative":{"exercise_price":2.86,"exercise_date":"2023-07-14","expiration_date":"2028-07-14","underlying":"Common Stock","underlying_shares":1237762},"source":{"system":"sec-edgar","filing":"0001104659-25-045416","document":"tm2514116-1_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/748592/000110465925045416/tm2514116-1_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-11-05"}},{"id":1156907,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"12.0% Senior Convertible Notes due December 12, 2028","published_at":"2025-05-07T15:48:22.000Z","date":"2024-09-24","kind":"sale","planned":false,"acquired":false,"reported_value":3000000,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On November 5, 2024, the Reporting Person filed a Form 4 that included an incorrect transaction date of October 29, 2024 for the Exchange Transactions (as defined below) based on the fact that under the Exchange Agreement (as defined below) consummation of the Exchange Transactions was conditioned upon Stockholder Approval (as defined in the Exchange Agreement). This amendment is being filed to reflect the correct transaction date for the Exchange Transactions of September 24, 2024 based on the analysis set forth in footnote 2 below."},{"field":"date","element":"transactionDate","label":"F2","text":"Upon review of the relevant facts and caselaw, the Reporting Person has determined that the Stockholder Approval was not a material condition for the Exchange Transactions as the Reporting Person and several other stockholders exchanging securities with the Company had entered into support agreements with the Issuer on September 24, 2024 (as disclosed in the Issuer's Current Report on Form 8-K filed with the SEC on September 25, 2024) pursuant to which each stockholder agreed to vote all of their eligible voting securities in favor of the Stockholder Approval. According to the Issuer's Definitive Proxy Statement filed with the SEC on October 7, 2024, the parties to the support agreements owned approximately 48% of the Issuer's outstanding Common Stock, which meant that the satisfaction of the condition was practically assured and the Reporting Person became irrevocably committed to the Exchange Transactions on September 24, 2024 after all parties entered into the support agreements."},{"field":"date","element":"transactionDate","label":"F4","text":"The Reporting Person also agreed pursuant to the Exchange Agreement to exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collectively with the Warrant Exchange, the \"Exchange Transactions\")."},{"field":"date","element":"transactionDate","label":"F5","text":"Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval, which occurred on October 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Reporting Person also agreed pursuant to the Exchange Agreement to exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collectively with the Warrant Exchange, the \"Exchange Transactions\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval, which occurred on October 29, 2024."}],"balance_after":0,"derivative":{"exercise_price":1.9194,"exercise_date":"2012-12-15","expiration_date":"2028-12-15","underlying":"Common Stock","underlying_shares":3125976},"source":{"system":"sec-edgar","filing":"0001104659-25-045416","document":"tm2514116-1_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/748592/000110465925045416/tm2514116-1_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-11-05"}},{"id":1156906,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-07T15:48:22.000Z","date":"2024-09-24","kind":"purchase","planned":false,"acquired":true,"shares":1562988,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On November 5, 2024, the Reporting Person filed a Form 4 that included an incorrect transaction date of October 29, 2024 for the Exchange Transactions (as defined below) based on the fact that under the Exchange Agreement (as defined below) consummation of the Exchange Transactions was conditioned upon Stockholder Approval (as defined in the Exchange Agreement). This amendment is being filed to reflect the correct transaction date for the Exchange Transactions of September 24, 2024 based on the analysis set forth in footnote 2 below."},{"field":"date","element":"transactionDate","label":"F2","text":"Upon review of the relevant facts and caselaw, the Reporting Person has determined that the Stockholder Approval was not a material condition for the Exchange Transactions as the Reporting Person and several other stockholders exchanging securities with the Company had entered into support agreements with the Issuer on September 24, 2024 (as disclosed in the Issuer's Current Report on Form 8-K filed with the SEC on September 25, 2024) pursuant to which each stockholder agreed to vote all of their eligible voting securities in favor of the Stockholder Approval. According to the Issuer's Definitive Proxy Statement filed with the SEC on October 7, 2024, the parties to the support agreements owned approximately 48% of the Issuer's outstanding Common Stock, which meant that the satisfaction of the condition was practically assured and the Reporting Person became irrevocably committed to the Exchange Transactions on September 24, 2024 after all parties entered into the support agreements."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the \"Exchange Agreement\"), pursuant to which the reporting person agreed to exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share (\"Common Stock\") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number) (the \"Warrant Exchange\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval, which occurred on October 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Shares issued pursuant to the Exchange Agreement in exchange for all of the reporting person's warrants to purchase shares of Common Stock at an exercise price of $1.43 per share with an expiration date of December 15, 2028."}],"balance_after":13808577,"source":{"system":"sec-edgar","filing":"0001104659-25-045416","document":"tm2514116-1_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/748592/000110465925045416/tm2514116-1_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-11-05"}},{"id":1156905,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-07T15:48:22.000Z","date":"2024-09-24","kind":"purchase","planned":false,"acquired":true,"shares":5420823,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On November 5, 2024, the Reporting Person filed a Form 4 that included an incorrect transaction date of October 29, 2024 for the Exchange Transactions (as defined below) based on the fact that under the Exchange Agreement (as defined below) consummation of the Exchange Transactions was conditioned upon Stockholder Approval (as defined in the Exchange Agreement). This amendment is being filed to reflect the correct transaction date for the Exchange Transactions of September 24, 2024 based on the analysis set forth in footnote 2 below."},{"field":"date","element":"transactionDate","label":"F2","text":"Upon review of the relevant facts and caselaw, the Reporting Person has determined that the Stockholder Approval was not a material condition for the Exchange Transactions as the Reporting Person and several other stockholders exchanging securities with the Company had entered into support agreements with the Issuer on September 24, 2024 (as disclosed in the Issuer's Current Report on Form 8-K filed with the SEC on September 25, 2024) pursuant to which each stockholder agreed to vote all of their eligible voting securities in favor of the Stockholder Approval. According to the Issuer's Definitive Proxy Statement filed with the SEC on October 7, 2024, the parties to the support agreements owned approximately 48% of the Issuer's outstanding Common Stock, which meant that the satisfaction of the condition was practically assured and the Reporting Person became irrevocably committed to the Exchange Transactions on September 24, 2024 after all parties entered into the support agreements."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Reporting Person also agreed pursuant to the Exchange Agreement to exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collectively with the Warrant Exchange, the \"Exchange Transactions\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval, which occurred on October 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Shares issued pursuant to the Exchange Agreement in exchange for all of the reporting person's 12.0% Senior Convertible Notes due December 12, 2028 in the aggregate principal amount of $3,000,000 plus applicable interest."}],"balance_after":12245589,"source":{"system":"sec-edgar","filing":"0001104659-25-045416","document":"tm2514116-1_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/748592/000110465925045416/tm2514116-1_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-11-05"}},{"id":1156904,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-07T15:48:22.000Z","date":"2024-09-24","kind":"purchase","planned":false,"acquired":true,"shares":1237762,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On November 5, 2024, the Reporting Person filed a Form 4 that included an incorrect transaction date of October 29, 2024 for the Exchange Transactions (as defined below) based on the fact that under the Exchange Agreement (as defined below) consummation of the Exchange Transactions was conditioned upon Stockholder Approval (as defined in the Exchange Agreement). This amendment is being filed to reflect the correct transaction date for the Exchange Transactions of September 24, 2024 based on the analysis set forth in footnote 2 below."},{"field":"date","element":"transactionDate","label":"F2","text":"Upon review of the relevant facts and caselaw, the Reporting Person has determined that the Stockholder Approval was not a material condition for the Exchange Transactions as the Reporting Person and several other stockholders exchanging securities with the Company had entered into support agreements with the Issuer on September 24, 2024 (as disclosed in the Issuer's Current Report on Form 8-K filed with the SEC on September 25, 2024) pursuant to which each stockholder agreed to vote all of their eligible voting securities in favor of the Stockholder Approval. According to the Issuer's Definitive Proxy Statement filed with the SEC on October 7, 2024, the parties to the support agreements owned approximately 48% of the Issuer's outstanding Common Stock, which meant that the satisfaction of the condition was practically assured and the Reporting Person became irrevocably committed to the Exchange Transactions on September 24, 2024 after all parties entered into the support agreements."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the \"Exchange Agreement\"), pursuant to which the reporting person agreed to exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share (\"Common Stock\") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number) (the \"Warrant Exchange\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval, which occurred on October 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Shares issued pursuant to the Exchange Agreement in exchange for all of the reporting person's warrants to purchase shares of Common Stock at an exercise price of $1.43 per share with an expiration date of July 14, 2028."}],"balance_after":6824766,"source":{"system":"sec-edgar","filing":"0001104659-25-045416","document":"tm2514116-1_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/748592/000110465925045416/tm2514116-1_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-11-05"}},{"id":1156903,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-07T15:48:22.000Z","date":"2024-09-24","kind":"purchase","planned":false,"acquired":true,"shares":4768783,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On November 5, 2024, the Reporting Person filed a Form 4 that included an incorrect transaction date of October 29, 2024 for the Exchange Transactions (as defined below) based on the fact that under the Exchange Agreement (as defined below) consummation of the Exchange Transactions was conditioned upon Stockholder Approval (as defined in the Exchange Agreement). This amendment is being filed to reflect the correct transaction date for the Exchange Transactions of September 24, 2024 based on the analysis set forth in footnote 2 below."},{"field":"date","element":"transactionDate","label":"F2","text":"Upon review of the relevant facts and caselaw, the Reporting Person has determined that the Stockholder Approval was not a material condition for the Exchange Transactions as the Reporting Person and several other stockholders exchanging securities with the Company had entered into support agreements with the Issuer on September 24, 2024 (as disclosed in the Issuer's Current Report on Form 8-K filed with the SEC on September 25, 2024) pursuant to which each stockholder agreed to vote all of their eligible voting securities in favor of the Stockholder Approval. According to the Issuer's Definitive Proxy Statement filed with the SEC on October 7, 2024, the parties to the support agreements owned approximately 48% of the Issuer's outstanding Common Stock, which meant that the satisfaction of the condition was practically assured and the Reporting Person became irrevocably committed to the Exchange Transactions on September 24, 2024 after all parties entered into the support agreements."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Reporting Person also agreed pursuant to the Exchange Agreement to exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collectively with the Warrant Exchange, the \"Exchange Transactions\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval, which occurred on October 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Shares issued pursuant to the Exchange Agreement in exchange for all of the reporting person's 6.0% Senior Convertible Promissory Notes due 2028 in the aggregate principal amount of $3,300,000 plus applicable interest."}],"balance_after":5587004,"source":{"system":"sec-edgar","filing":"0001104659-25-045416","document":"tm2514116-1_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/748592/000110465925045416/tm2514116-1_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-11-05"}},{"id":1156902,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-07T15:48:22.000Z","date":"2024-09-24","kind":"purchase","planned":false,"acquired":true,"shares":261756,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On November 5, 2024, the Reporting Person filed a Form 4 that included an incorrect transaction date of October 29, 2024 for the Exchange Transactions (as defined below) based on the fact that under the Exchange Agreement (as defined below) consummation of the Exchange Transactions was conditioned upon Stockholder Approval (as defined in the Exchange Agreement). This amendment is being filed to reflect the correct transaction date for the Exchange Transactions of September 24, 2024 based on the analysis set forth in footnote 2 below."},{"field":"date","element":"transactionDate","label":"F2","text":"Upon review of the relevant facts and caselaw, the Reporting Person has determined that the Stockholder Approval was not a material condition for the Exchange Transactions as the Reporting Person and several other stockholders exchanging securities with the Company had entered into support agreements with the Issuer on September 24, 2024 (as disclosed in the Issuer's Current Report on Form 8-K filed with the SEC on September 25, 2024) pursuant to which each stockholder agreed to vote all of their eligible voting securities in favor of the Stockholder Approval. According to the Issuer's Definitive Proxy Statement filed with the SEC on October 7, 2024, the parties to the support agreements owned approximately 48% of the Issuer's outstanding Common Stock, which meant that the satisfaction of the condition was practically assured and the Reporting Person became irrevocably committed to the Exchange Transactions on September 24, 2024 after all parties entered into the support agreements."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the \"Exchange Agreement\"), pursuant to which the reporting person agreed to exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share (\"Common Stock\") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number) (the \"Warrant Exchange\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval, which occurred on October 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Shares issued pursuant to the Exchange Agreement in exchange for all of the reporting person's warrants to purchase shares of Common Stock at an exercise price of $1.43 per share with an expiration date of June 2, 2028."}],"balance_after":818221,"source":{"system":"sec-edgar","filing":"0001104659-25-045416","document":"tm2514116-1_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/748592/000110465925045416/tm2514116-1_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-11-05"}},{"id":1178425,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-04T14:54:24.000Z","date":"2025-04-02","kind":"purchase","planned":false,"acquired":true,"shares":3768397,"price":0.1046,"value":394174.3262,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 2, 2025, pursuant to a private placement offering by the Issuer, the reporting person acquired 3,768,397 shares of the Issuer's Common Stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On December 3, 2024, the Issuer paid a dividend to all holders of record of its Series A Preferred Stock on such date of $0.05 per share of Series A Preferred Stock. Pursuant to the terms of the Series A Preferred Stock, the Issuer elected to pay the dividend in an equivalent amount of common stock. As a result, the Reporting Person received 5,082 shares of the Issuer's common stock."}],"balance_after":20401602,"source":{"system":"sec-edgar","filing":"0001104659-25-032060","document":"tm2511399-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/748592/000110465925032060/tm2511399-2_4seq1.xml","form_type":"4"}},{"id":1376633,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (right to buy)","published_at":"2024-11-05T17:42:38.000Z","date":"2024-10-29","kind":"sale","planned":false,"acquired":false,"shares":3125976,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the \"Exchange Agreement\"), pursuant to which the reporting person agreed to (i) exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share (\"Common Stock\") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number), and"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"(ii) exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collective, the \"Exchange Transactions\"). Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval (as defined in the Exchange Agreement), which occurred on October 29, 2024."},{"field":"date","element":"transactionDate","label":"F1","text":"The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the \"Exchange Agreement\"), pursuant to which the reporting person agreed to (i) exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share (\"Common Stock\") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number), and"},{"field":"date","element":"transactionDate","label":"F2","text":"(ii) exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collective, the \"Exchange Transactions\"). Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval (as defined in the Exchange Agreement), which occurred on October 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the \"Exchange Agreement\"), pursuant to which the reporting person agreed to (i) exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share (\"Common Stock\") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number), and"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(ii) exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collective, the \"Exchange Transactions\"). Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval (as defined in the Exchange Agreement), which occurred on October 29, 2024."}],"balance_after":0,"derivative":{"exercise_price":1.43,"exercise_date":"2023-12-15","expiration_date":"2028-12-15","underlying":"Common Stock","underlying_shares":3125976},"source":{"system":"sec-edgar","filing":"0001104659-24-114222","document":"tm2427444-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/748592/000110465924114222/tm2427444-1_4seq1.xml","form_type":"4"}},{"id":1376632,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (right to buy)","published_at":"2024-11-05T17:42:38.000Z","date":"2024-10-29","kind":"sale","planned":false,"acquired":false,"shares":2475524,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the \"Exchange Agreement\"), pursuant to which the reporting person agreed to (i) exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share (\"Common Stock\") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number), and"},{"field":"date","element":"transactionDate","label":"F2","text":"(ii) exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collective, the \"Exchange Transactions\"). Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval (as defined in the Exchange Agreement), which occurred on October 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the \"Exchange Agreement\"), pursuant to which the reporting person agreed to (i) exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share (\"Common Stock\") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number), and"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(ii) exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collective, the \"Exchange Transactions\"). Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval (as defined in the Exchange Agreement), which occurred on October 29, 2024."}],"balance_after":0,"derivative":{"exercise_price":1.43,"exercise_date":"2023-12-14","expiration_date":"2028-07-14","underlying":"Common Stock","underlying_shares":2475524},"source":{"system":"sec-edgar","filing":"0001104659-24-114222","document":"tm2427444-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/748592/000110465924114222/tm2427444-1_4seq1.xml","form_type":"4"}},{"id":1376631,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (right to buy)","published_at":"2024-11-05T17:42:38.000Z","date":"2024-10-29","kind":"sale","planned":false,"acquired":false,"shares":523512,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the \"Exchange Agreement\"), pursuant to which the reporting person agreed to (i) exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share (\"Common Stock\") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number), and"},{"field":"date","element":"transactionDate","label":"F2","text":"(ii) exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collective, the \"Exchange Transactions\"). Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval (as defined in the Exchange Agreement), which occurred on October 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the \"Exchange Agreement\"), pursuant to which the reporting person agreed to (i) exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share (\"Common Stock\") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number), and"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(ii) exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collective, the \"Exchange Transactions\"). Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval (as defined in the Exchange Agreement), which occurred on October 29, 2024."}],"balance_after":0,"derivative":{"exercise_price":1.43,"exercise_date":"2023-12-14","expiration_date":"2028-06-02","underlying":"Common Stock","underlying_shares":523512},"source":{"system":"sec-edgar","filing":"0001104659-24-114222","document":"tm2427444-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/748592/000110465924114222/tm2427444-1_4seq1.xml","form_type":"4"}},{"id":1376630,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"6.0% Senior Convertible Promissory Notes due 2028","published_at":"2024-11-05T17:42:38.000Z","date":"2024-10-29","kind":"sale","planned":false,"acquired":false,"reported_value":3540000,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the \"Exchange Agreement\"), pursuant to which the reporting person agreed to (i) exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share (\"Common Stock\") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number), and"},{"field":"date","element":"transactionDate","label":"F2","text":"(ii) exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collective, the \"Exchange Transactions\"). Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval (as defined in the Exchange Agreement), which occurred on October 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the \"Exchange Agreement\"), pursuant to which the reporting person agreed to (i) exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share (\"Common Stock\") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number), and"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(ii) exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collective, the \"Exchange Transactions\"). Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval (as defined in the Exchange Agreement), which occurred on October 29, 2024."}],"balance_after":0,"derivative":{"exercise_price":2.86,"exercise_date":"2023-07-14","expiration_date":"2028-07-14","underlying":"Common Stock","underlying_shares":1237762},"source":{"system":"sec-edgar","filing":"0001104659-24-114222","document":"tm2427444-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/748592/000110465924114222/tm2427444-1_4seq1.xml","form_type":"4"}},{"id":1376629,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"12.0% Senior Convertible Notes due December 12, 2028","published_at":"2024-11-05T17:42:38.000Z","date":"2024-10-29","kind":"sale","planned":false,"acquired":false,"reported_value":3000000,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the \"Exchange Agreement\"), pursuant to which the reporting person agreed to (i) exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share (\"Common Stock\") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number), and"},{"field":"date","element":"transactionDate","label":"F2","text":"(ii) exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collective, the \"Exchange Transactions\"). Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval (as defined in the Exchange Agreement), which occurred on October 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the \"Exchange Agreement\"), pursuant to which the reporting person agreed to (i) exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share (\"Common Stock\") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number), and"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(ii) exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collective, the \"Exchange Transactions\"). Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval (as defined in the Exchange Agreement), which occurred on October 29, 2024."}],"balance_after":0,"derivative":{"exercise_price":1.9194,"exercise_date":"2012-12-15","expiration_date":"2028-12-15","underlying":"Common Stock","underlying_shares":3125976},"source":{"system":"sec-edgar","filing":"0001104659-24-114222","document":"tm2427444-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/748592/000110465924114222/tm2427444-1_4seq1.xml","form_type":"4"}},{"id":1376628,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"12.0% Senior Convertible Notes due September 24, 2025","published_at":"2024-11-05T17:42:38.000Z","date":"2024-10-29","kind":"exercise","planned":false,"acquired":false,"price":0,"reported_value":1368626,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The Notes are automatically converted into shares of Common Stock upon the obtaining of Stockholder Approval (as defined in the Notes) and cannot be converted into Common Stock prior to obtaining Stockholder Approval."}],"balance_after":0,"derivative":{"exercise_price":0.5,"expiration_date":"2025-09-24","underlying":"Common Stock","underlying_shares":2737252},"source":{"system":"sec-edgar","filing":"0001104659-24-114222","document":"tm2427444-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/748592/000110465924114222/tm2427444-1_4seq1.xml","form_type":"4"}},{"id":1376627,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"12.0% Senior Convertible Notes due September 24, 2025","published_at":"2024-11-05T17:42:38.000Z","date":"2024-09-24","kind":"purchase","planned":false,"acquired":true,"price":1368626,"reported_value":1368626,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F11","text":"The reporting person entered into a Note Purchase Agreement with the Issuer on September 24, 2024, pursuant to which the reporting person acquired $1,368,626 principal amount of September Notes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The Notes are automatically converted into shares of Common Stock upon the obtaining of Stockholder Approval (as defined in the Notes) and cannot be converted into Common Stock prior to obtaining Stockholder Approval."}],"derivative":{"exercise_price":0.5,"expiration_date":"2025-09-24","underlying":"Common Stock","underlying_shares":2737252},"source":{"system":"sec-edgar","filing":"0001104659-24-114222","document":"tm2427444-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/748592/000110465924114222/tm2427444-1_4seq1.xml","form_type":"4"}},{"id":1376626,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (right to buy)","published_at":"2024-11-05T17:42:38.000Z","date":"2024-09-23","kind":"purchase","planned":false,"acquired":true,"shares":83916,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F10","text":"On September 23, 2024, the reporting person agreed to forgive a personal loan for $50,000 to a second investor (separate from the investor referenced in footnote 9) in the Issuer's July 2023 private placement in exchange for all of such invetsor's warrants to purchase shares of Common Stock and 6.0% Senior Convertible Promissory Notes due 2028."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"On September 23, 2024, the reporting person agreed to forgive a personal loan for $50,000 to a second investor (separate from the investor referenced in footnote 9) in the Issuer's July 2023 private placement in exchange for all of such invetsor's warrants to purchase shares of Common Stock and 6.0% Senior Convertible Promissory Notes due 2028."}],"balance_after":2475524,"derivative":{"exercise_price":1.43,"exercise_date":"2023-12-14","expiration_date":"2028-07-14","underlying":"Common Stock","underlying_shares":83916},"source":{"system":"sec-edgar","filing":"0001104659-24-114222","document":"tm2427444-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/748592/000110465924114222/tm2427444-1_4seq1.xml","form_type":"4"}},{"id":1376625,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"6.0% Senior Convertible Promissory Notes due 2028","published_at":"2024-11-05T17:42:38.000Z","date":"2024-09-23","kind":"purchase","planned":false,"acquired":true,"reported_value":120000,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F10","text":"On September 23, 2024, the reporting person agreed to forgive a personal loan for $50,000 to a second investor (separate from the investor referenced in footnote 9) in the Issuer's July 2023 private placement in exchange for all of such invetsor's warrants to purchase shares of Common Stock and 6.0% Senior Convertible Promissory Notes due 2028."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"On September 23, 2024, the reporting person agreed to forgive a personal loan for $50,000 to a second investor (separate from the investor referenced in footnote 9) in the Issuer's July 2023 private placement in exchange for all of such invetsor's warrants to purchase shares of Common Stock and 6.0% Senior Convertible Promissory Notes due 2028."}],"derivative":{"exercise_price":2.86,"exercise_date":"2023-07-14","expiration_date":"2028-07-14","underlying":"Common Stock","underlying_shares":41958},"source":{"system":"sec-edgar","filing":"0001104659-24-114222","document":"tm2427444-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/748592/000110465924114222/tm2427444-1_4seq1.xml","form_type":"4"}},{"id":1376624,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (right to buy)","published_at":"2024-11-05T17:42:38.000Z","date":"2024-09-23","kind":"purchase","planned":false,"acquired":true,"shares":83916,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F9","text":"On September 23, 2024, the reporting person agreed to forgive a personal loan to an investor in the Issuer's July 2023 private placement for $50,000 in exchange for all of such investor's warrants to purchase shares of Common Stock and 6.0% Senior Convertible Promissory Notes due 2028."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"On September 23, 2024, the reporting person agreed to forgive a personal loan to an investor in the Issuer's July 2023 private placement for $50,000 in exchange for all of such investor's warrants to purchase shares of Common Stock and 6.0% Senior Convertible Promissory Notes due 2028."}],"balance_after":2391608,"derivative":{"exercise_price":1.43,"exercise_date":"2023-12-14","expiration_date":"2028-07-14","underlying":"Common Stock","underlying_shares":83916},"source":{"system":"sec-edgar","filing":"0001104659-24-114222","document":"tm2427444-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/748592/000110465924114222/tm2427444-1_4seq1.xml","form_type":"4"}},{"id":1376623,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"6.0% Senior Convertible Promissory Notes due 2028","published_at":"2024-11-05T17:42:38.000Z","date":"2024-09-23","kind":"purchase","planned":false,"acquired":true,"reported_value":120000,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F9","text":"On September 23, 2024, the reporting person agreed to forgive a personal loan to an investor in the Issuer's July 2023 private placement for $50,000 in exchange for all of such investor's warrants to purchase shares of Common Stock and 6.0% Senior Convertible Promissory Notes due 2028."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"On September 23, 2024, the reporting person agreed to forgive a personal loan to an investor in the Issuer's July 2023 private placement for $50,000 in exchange for all of such investor's warrants to purchase shares of Common Stock and 6.0% Senior Convertible Promissory Notes due 2028."}],"derivative":{"exercise_price":2.86,"exercise_date":"2023-07-14","expiration_date":"2028-07-14","underlying":"Common Stock","underlying_shares":41958},"source":{"system":"sec-edgar","filing":"0001104659-24-114222","document":"tm2427444-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/748592/000110465924114222/tm2427444-1_4seq1.xml","form_type":"4"}},{"id":1376622,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-05T17:42:38.000Z","date":"2024-10-29","kind":"exercise","planned":false,"acquired":true,"shares":2819546,"price":0.5,"value":1409773.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F8","text":"Shares issued as a result the conversion of the Issuer's 12.0% Senior Convertible Notes due September 24, 2025 (the \"September Notes\") consisting of (i) 2,737,252 shares of Common Stock issued upon conversion of the principal amount of the September Notes and (ii) 82,294 shares issued upon conversion of the interest accrued on the September Notes."}],"balance_after":16628123,"source":{"system":"sec-edgar","filing":"0001104659-24-114222","document":"tm2427444-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/748592/000110465924114222/tm2427444-1_4seq1.xml","form_type":"4"}},{"id":1376621,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-05T17:42:38.000Z","date":"2024-10-29","kind":"purchase","planned":false,"acquired":true,"shares":1562988,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the \"Exchange Agreement\"), pursuant to which the reporting person agreed to (i) exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share (\"Common Stock\") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number), and"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(ii) exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collective, the \"Exchange Transactions\"). Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval (as defined in the Exchange Agreement), which occurred on October 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Shares issued pursuant to the Exchange Agreement in exchange for all of the reporting person's warrants to purchase shares of Common Stock at an exercise price of $1.43 per share with an expiration date of December 15, 2028."}],"balance_after":13808577,"source":{"system":"sec-edgar","filing":"0001104659-24-114222","document":"tm2427444-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/748592/000110465924114222/tm2427444-1_4seq1.xml","form_type":"4"}},{"id":1376620,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-05T17:42:38.000Z","date":"2024-10-29","kind":"purchase","planned":false,"acquired":true,"shares":5420823,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the \"Exchange Agreement\"), pursuant to which the reporting person agreed to (i) exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share (\"Common Stock\") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number), and"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(ii) exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collective, the \"Exchange Transactions\"). Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval (as defined in the Exchange Agreement), which occurred on October 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Shares issued pursuant to the Exchange Agreement in exchange for all of the reporting person's 12.0% Senior Convertible Notes due December 12, 2028 in the aggregate principal amount of $3,000,000 plus applicable interest."}],"balance_after":12245589,"source":{"system":"sec-edgar","filing":"0001104659-24-114222","document":"tm2427444-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/748592/000110465924114222/tm2427444-1_4seq1.xml","form_type":"4"}},{"id":1376619,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-05T17:42:38.000Z","date":"2024-10-29","kind":"purchase","planned":false,"acquired":true,"shares":1237762,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the \"Exchange Agreement\"), pursuant to which the reporting person agreed to (i) exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share (\"Common Stock\") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number), and"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(ii) exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collective, the \"Exchange Transactions\"). Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval (as defined in the Exchange Agreement), which occurred on October 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Shares issued pursuant to the Exchange Agreement in exchange for all of the reporting person's warrants to purchase shares of Common Stock at an exercise price of $1.43 per share with an expiration date of July 14, 2028."}],"balance_after":6824766,"source":{"system":"sec-edgar","filing":"0001104659-24-114222","document":"tm2427444-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/748592/000110465924114222/tm2427444-1_4seq1.xml","form_type":"4"}},{"id":1376618,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-05T17:42:38.000Z","date":"2024-10-29","kind":"purchase","planned":false,"acquired":true,"shares":4768783,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the \"Exchange Agreement\"), pursuant to which the reporting person agreed to (i) exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share (\"Common Stock\") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number), and"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(ii) exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collective, the \"Exchange Transactions\"). Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval (as defined in the Exchange Agreement), which occurred on October 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Shares issued pursuant to the Exchange Agreement in exchange for all of the reporting person's 6.0% Senior Convertible Promissory Notes due 2028 in the aggregate principal amount of $3,300,000 plus applicable interest."}],"balance_after":5587004,"source":{"system":"sec-edgar","filing":"0001104659-24-114222","document":"tm2427444-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/748592/000110465924114222/tm2427444-1_4seq1.xml","form_type":"4"}},{"id":1376617,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-05T17:42:38.000Z","date":"2024-10-29","kind":"purchase","planned":false,"acquired":true,"shares":261756,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the \"Exchange Agreement\"), pursuant to which the reporting person agreed to (i) exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share (\"Common Stock\") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number), and"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(ii) exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collective, the \"Exchange Transactions\"). Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval (as defined in the Exchange Agreement), which occurred on October 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Shares issued pursuant to the Exchange Agreement in exchange for all of the reporting person's warrants to purchase shares of Common Stock at an exercise price of $1.43 per share with an expiration date of June 2, 2028."}],"balance_after":818221,"source":{"system":"sec-edgar","filing":"0001104659-24-114222","document":"tm2427444-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/748592/000110465924114222/tm2427444-1_4seq1.xml","form_type":"4"}},{"id":1692070,"issuer":{"id":94670,"kind":"organization","name":"Comera Life Sciences Holdings, Inc.","symbol":"CMRA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Perpetual Preferred Stock","published_at":"2024-01-03T20:38:12.000Z","date":"2023-12-27","kind":"purchase","planned":false,"acquired":true,"shares":3895.53,"price":500000,"value":1947765000.0,"ownership":{"direct":false,"nature":"By LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The preferred stock was acquired by Comera SPV LLC (\"SPV\") in a private transaction pursuant to a purchase agreement, dated as of December 27, 2023, with an unaffiliated, institutional investor."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The preferred stock is perpetual and therefore has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person is the General Partner of SPV. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":3895.53,"derivative":{"exercise_price":12.56,"exercise_date":"2023-12-27","underlying":"Common Stock","underlying_shares":310153},"source":{"system":"sec-edgar","filing":"0001104659-24-001041","document":"tm241917-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1448698/000110465924001041/tm241917-1_4seq1.xml","form_type":"4"}},{"id":1692069,"issuer":{"id":94670,"kind":"organization","name":"Comera Life Sciences Holdings, Inc.","symbol":"CMRA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2024-01-03T20:38:12.000Z","date":"2023-12-29","kind":"purchase","planned":false,"acquired":true,"shares":20650908,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person entered into a Securities Purchase Agreement with the Issuer on December 29, 2023, pursuant to which the reporting person acquired (i) $567,900 principal amount of the Issuer's 12.0% Senior Secured Convertible Notes (the \"Notes\") and (ii) 20,650,908 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.0001 per share (\"Common Stock\"), at an exercise price of $0.055 per share (the \"Warrants\"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person entered into a Securities Purchase Agreement with the Issuer on December 29, 2023, pursuant to which the reporting person acquired (i) $567,900 principal amount of the Issuer's 12.0% Senior Secured Convertible Notes (the \"Notes\") and (ii) 20,650,908 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.0001 per share (\"Common Stock\"), at an exercise price of $0.055 per share (the \"Warrants\"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof."}],"balance_after":20650908,"derivative":{"exercise_price":0.055,"exercise_date":"2023-12-29","expiration_date":"2028-12-29","underlying":"Common Stock","underlying_shares":20650908},"source":{"system":"sec-edgar","filing":"0001104659-24-001041","document":"tm241917-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1448698/000110465924001041/tm241917-1_4seq1.xml","form_type":"4"}},{"id":1692068,"issuer":{"id":94670,"kind":"organization","name":"Comera Life Sciences Holdings, Inc.","symbol":"CMRA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"12.0% Senior Secured Convertible Notes","published_at":"2024-01-03T20:38:12.000Z","date":"2023-12-29","kind":"purchase","planned":false,"acquired":true,"price":567900,"reported_value":567900,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person entered into a Securities Purchase Agreement with the Issuer on December 29, 2023, pursuant to which the reporting person acquired (i) $567,900 principal amount of the Issuer's 12.0% Senior Secured Convertible Notes (the \"Notes\") and (ii) 20,650,908 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.0001 per share (\"Common Stock\"), at an exercise price of $0.055 per share (the \"Warrants\"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof."}],"derivative":{"exercise_price":0.055,"exercise_date":"2023-12-29","expiration_date":"2024-12-29","underlying":"Common Stock","underlying_shares":10325454},"source":{"system":"sec-edgar","filing":"0001104659-24-001041","document":"tm241917-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1448698/000110465924001041/tm241917-1_4seq1.xml","form_type":"4"}},{"id":1703923,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (right to buy)","published_at":"2023-12-20T15:05:17.000Z","date":"2023-12-14","kind":"purchase","planned":false,"acquired":true,"shares":523512,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transactions reported in Table II above involved the amendment of an outstanding warrant issued on December 2, 2022 to reduce the exercise price from $3.28 per share to $1.43 per share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new one."}],"balance_after":523512,"derivative":{"exercise_price":1.43,"exercise_date":"2023-12-14","expiration_date":"2028-06-02","underlying":"Common Stock","underlying_shares":523512},"source":{"system":"sec-edgar","filing":"0001104659-23-127551","document":"tm2333295-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/748592/000110465923127551/tm2333295-1_4seq1.xml","form_type":"4"}},{"id":1703922,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (right to buy)","published_at":"2023-12-20T15:05:17.000Z","date":"2023-12-14","kind":"other","planned":false,"acquired":false,"shares":523512,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transactions reported in Table II above involved the amendment of an outstanding warrant issued on December 2, 2022 to reduce the exercise price from $3.28 per share to $1.43 per share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new one."}],"balance_after":0,"derivative":{"exercise_price":3.28,"exercise_date":"2023-06-02","expiration_date":"2028-06-02","underlying":"Common Stock","underlying_shares":523512},"source":{"system":"sec-edgar","filing":"0001104659-23-127551","document":"tm2333295-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/748592/000110465923127551/tm2333295-1_4seq1.xml","form_type":"4"}},{"id":1703921,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (right to buy)","published_at":"2023-12-20T15:05:17.000Z","date":"2023-12-14","kind":"purchase","planned":false,"acquired":true,"shares":2307692,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported in Table II above involved the amendment of an outstanding warrant issued on July 14, 2023 to reduce the exercise price from $2.61 per share to $1.43 per share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new one."}],"balance_after":2307692,"derivative":{"exercise_price":1.43,"exercise_date":"2023-12-14","expiration_date":"2028-07-14","underlying":"Common Stock","underlying_shares":2307692},"source":{"system":"sec-edgar","filing":"0001104659-23-127551","document":"tm2333295-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/748592/000110465923127551/tm2333295-1_4seq1.xml","form_type":"4"}},{"id":1703920,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (right to buy)","published_at":"2023-12-20T15:05:17.000Z","date":"2023-12-14","kind":"other","planned":false,"acquired":false,"shares":2307692,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported in Table II above involved the amendment of an outstanding warrant issued on July 14, 2023 to reduce the exercise price from $2.61 per share to $1.43 per share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new one."}],"balance_after":0,"derivative":{"exercise_price":2.61,"exercise_date":"2023-07-14","expiration_date":"2028-07-14","underlying":"Common Stock","underlying_shares":2307692},"source":{"system":"sec-edgar","filing":"0001104659-23-127551","document":"tm2333295-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/748592/000110465923127551/tm2333295-1_4seq1.xml","form_type":"4"}},{"id":1703919,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (right to buy)","published_at":"2023-12-20T15:05:17.000Z","date":"2023-12-14","kind":"purchase","planned":false,"acquired":true,"shares":3125976,"price":0.125,"value":390747.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The reporting person entered into a Securities Purchase Agreement with the Issuer on December 14, 2023, pursuant to which, on December 15, 2023, the reporting person acquired (i) $3,000,000 principal amount of the Issuer's 12.0% Senior Convertible Notes (the \"Notes\") and (ii) 3,125,976 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.005 per share (\"Common Stock\"), at an exercise price of $1.43 per share (the \"Warrants\"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. The conversion price for each Note included $0.25 ($0.125 for each Warrant) in accordance with Nasdaq rules."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person entered into a Securities Purchase Agreement with the Issuer on December 14, 2023, pursuant to which, on December 15, 2023, the reporting person acquired (i) $3,000,000 principal amount of the Issuer's 12.0% Senior Convertible Notes (the \"Notes\") and (ii) 3,125,976 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.005 per share (\"Common Stock\"), at an exercise price of $1.43 per share (the \"Warrants\"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. The conversion price for each Note included $0.25 ($0.125 for each Warrant) in accordance with Nasdaq rules."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The exercisability of the Warrants is subject to a 19.99% beneficial ownership limitation."}],"balance_after":3125976,"derivative":{"exercise_price":1.43,"exercise_date":"2023-12-15","expiration_date":"2028-12-15","underlying":"Common Stock","underlying_shares":3125976},"source":{"system":"sec-edgar","filing":"0001104659-23-127551","document":"tm2333295-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/748592/000110465923127551/tm2333295-1_4seq1.xml","form_type":"4"}},{"id":1703918,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"12.0% Senior Convertible Notes","published_at":"2023-12-20T15:05:17.000Z","date":"2023-12-14","kind":"purchase","planned":false,"acquired":true,"price":3000000,"reported_value":3000000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The reporting person entered into a Securities Purchase Agreement with the Issuer on December 14, 2023, pursuant to which, on December 15, 2023, the reporting person acquired (i) $3,000,000 principal amount of the Issuer's 12.0% Senior Convertible Notes (the \"Notes\") and (ii) 3,125,976 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.005 per share (\"Common Stock\"), at an exercise price of $1.43 per share (the \"Warrants\"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. The conversion price for each Note included $0.25 ($0.125 for each Warrant) in accordance with Nasdaq rules."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"The conversion of the Notes is subject to a 19.99% beneficial ownership limitation."}],"derivative":{"exercise_price":1.9194,"exercise_date":"2023-12-15","expiration_date":"2028-12-15","underlying":"Common Stock","underlying_shares":1562988},"source":{"system":"sec-edgar","filing":"0001104659-23-127551","document":"tm2333295-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/748592/000110465923127551/tm2333295-1_4seq1.xml","form_type":"4"}},{"id":1783846,"issuer":{"id":94670,"kind":"organization","name":"Comera Life Sciences Holdings, Inc.","symbol":"CMRA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2023-09-11T20:24:50.000Z","date":"2023-09-11","kind":"purchase","planned":false,"acquired":true,"shares":5134474,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 11, 2023, pursuant to a private placement offering by the Issuer and following the receipt of stockholder approval, the Reporting Person acquired 2,053,789 shares of the Issuer's Common Stock and Warrants to purchase up to 5,134,474 shares of Common Stock. The combined purchase price per share of Common Stock and accompanying Warrant in the offering was $0.51125, with all of the purchase price allocated to the shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 11, 2023, pursuant to a private placement offering by the Issuer and following the receipt of stockholder approval, the Reporting Person acquired 2,053,789 shares of the Issuer's Common Stock and Warrants to purchase up to 5,134,474 shares of Common Stock. The combined purchase price per share of Common Stock and accompanying Warrant in the offering was $0.51125, with all of the purchase price allocated to the shares of Common Stock."}],"balance_after":5134474,"derivative":{"exercise_price":0.6135,"exercise_date":"2023-09-11","expiration_date":"2028-09-11","underlying":"Common Stock","underlying_shares":5134474},"source":{"system":"sec-edgar","filing":"0001104659-23-099800","document":"tm2325724-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1448698/000110465923099800/tm2325724-1_4seq1.xml","form_type":"4"}},{"id":1783845,"issuer":{"id":94670,"kind":"organization","name":"Comera Life Sciences Holdings, Inc.","symbol":"CMRA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-11T20:24:50.000Z","date":"2023-09-11","kind":"purchase","planned":false,"acquired":true,"shares":2053789,"price":0.5112,"value":1049896.9368,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 11, 2023, pursuant to a private placement offering by the Issuer and following the receipt of stockholder approval, the Reporting Person acquired 2,053,789 shares of the Issuer's Common Stock and Warrants to purchase up to 5,134,474 shares of Common Stock. The combined purchase price per share of Common Stock and accompanying Warrant in the offering was $0.51125, with all of the purchase price allocated to the shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 11, 2023, pursuant to a private placement offering by the Issuer and following the receipt of stockholder approval, the Reporting Person acquired 2,053,789 shares of the Issuer's Common Stock and Warrants to purchase up to 5,134,474 shares of Common Stock. The combined purchase price per share of Common Stock and accompanying Warrant in the offering was $0.51125, with all of the purchase price allocated to the shares of Common Stock."}],"balance_after":5813650,"source":{"system":"sec-edgar","filing":"0001104659-23-099800","document":"tm2325724-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1448698/000110465923099800/tm2325724-1_4seq1.xml","form_type":"4"}},{"id":1797247,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (right to buy)","published_at":"2023-08-25T23:34:23.000Z","date":"2023-07-13","kind":"purchase","planned":false,"acquired":true,"shares":2307692,"price":0.125,"value":288461.5,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The reporting person entered into a Securities Purchase Agreement with the Issuer on July 13, 2023, pursuant to which, on July 14, 2023, the reporting person acquired (i) $3,300,000 principal amount of the Issuer's 6.0% Senior Convertible Promissory Notes due July 2028 (the \"Notes\") and (ii) 2,307,692 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.005 per share (\"Common Stock\"), at an exercise price of $2.61 per share (the \"Warrants\"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. The conversion price for each Note included $0.25 ($0.125 for each Warrant) in accordance with Nasdaq rules."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person entered into a Securities Purchase Agreement with the Issuer on July 13, 2023, pursuant to which, on July 14, 2023, the reporting person acquired (i) $3,300,000 principal amount of the Issuer's 6.0% Senior Convertible Promissory Notes due July 2028 (the \"Notes\") and (ii) 2,307,692 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.005 per share (\"Common Stock\"), at an exercise price of $2.61 per share (the \"Warrants\"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. The conversion price for each Note included $0.25 ($0.125 for each Warrant) in accordance with Nasdaq rules."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The exercisability of the Warrants is subject to a 19.99% beneficial ownership limitation."}],"balance_after":2307692,"derivative":{"exercise_price":2.61,"exercise_date":"2023-07-14","expiration_date":"2028-07-14","underlying":"Common Stock","underlying_shares":2307692},"source":{"system":"sec-edgar","filing":"0001104659-23-095434","document":"tm2323568-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/748592/000110465923095434/tm2323568-3_4seq1.xml","form_type":"4"}},{"id":1797246,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"6.0% Senior Convertible Promissory Notes due 2028","published_at":"2023-08-25T23:34:23.000Z","date":"2023-07-13","kind":"purchase","planned":false,"acquired":true,"price":3300000,"reported_value":3300000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The reporting person entered into a Securities Purchase Agreement with the Issuer on July 13, 2023, pursuant to which, on July 14, 2023, the reporting person acquired (i) $3,300,000 principal amount of the Issuer's 6.0% Senior Convertible Promissory Notes due July 2028 (the \"Notes\") and (ii) 2,307,692 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.005 per share (\"Common Stock\"), at an exercise price of $2.61 per share (the \"Warrants\"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. The conversion price for each Note included $0.25 ($0.125 for each Warrant) in accordance with Nasdaq rules."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"The conversion of the Notes is subject to a 19.99% beneficial ownership limitation."}],"derivative":{"exercise_price":2.86,"exercise_date":"2023-07-14","expiration_date":"2028-07-14","underlying":"Common Stock","underlying_shares":1153846},"source":{"system":"sec-edgar","filing":"0001104659-23-095434","document":"tm2323568-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/748592/000110465923095434/tm2323568-3_4seq1.xml","form_type":"4"}},{"id":1796299,"issuer":{"id":94670,"kind":"organization","name":"Comera Life Sciences Holdings, Inc.","symbol":"CMRA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2023-08-25T19:33:47.000Z","date":"2023-07-31","kind":"purchase","planned":false,"acquired":true,"shares":2200488,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 31, 2023, pursuant to a private placement offering by the Issuer, the Reporting Person acquired 880,195 shares of the Issuer's Common Stock and Warrants to purchase up to 2,200,488 shares of Common Stock. The combined purchase price per share of Common Stock and accompanying Warrant in the offering was $0.51125, with all of the purchase price allocated to the shares of Common Stock."},{"field":"shares","element":"transactionShares","label":"F6","text":"The exercisability of the Warrants is subject to a 19.99% beneficial ownership limitation."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 31, 2023, pursuant to a private placement offering by the Issuer, the Reporting Person acquired 880,195 shares of the Issuer's Common Stock and Warrants to purchase up to 2,200,488 shares of Common Stock. The combined purchase price per share of Common Stock and accompanying Warrant in the offering was $0.51125, with all of the purchase price allocated to the shares of Common Stock."}],"balance_after":2200488,"derivative":{"exercise_price":0.6135,"exercise_date":"2024-02-01","expiration_date":"2028-07-31","underlying":"Common Stock","underlying_shares":2200488},"source":{"system":"sec-edgar","filing":"0001104659-23-095433","document":"tm2323568-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1448698/000110465923095433/tm2323568-1_4seq1.xml","form_type":"4"}},{"id":1796298,"issuer":{"id":94670,"kind":"organization","name":"Comera Life Sciences Holdings, Inc.","symbol":"CMRA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-25T19:33:47.000Z","date":"2023-07-31","kind":"purchase","planned":false,"acquired":true,"shares":880195,"price":0.5113,"value":450043.7035,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 31, 2023, pursuant to a private placement offering by the Issuer, the Reporting Person acquired 880,195 shares of the Issuer's Common Stock and Warrants to purchase up to 2,200,488 shares of Common Stock. The combined purchase price per share of Common Stock and accompanying Warrant in the offering was $0.51125, with all of the purchase price allocated to the shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 31, 2023, pursuant to a private placement offering by the Issuer, the Reporting Person acquired 880,195 shares of the Issuer's Common Stock and Warrants to purchase up to 2,200,488 shares of Common Stock. The combined purchase price per share of Common Stock and accompanying Warrant in the offering was $0.51125, with all of the purchase price allocated to the shares of Common Stock."}],"balance_after":3759861,"source":{"system":"sec-edgar","filing":"0001104659-23-095433","document":"tm2323568-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1448698/000110465923095433/tm2323568-1_4seq1.xml","form_type":"4"}},{"id":2060284,"issuer":{"id":94670,"kind":"organization","name":"Comera Life Sciences Holdings, Inc.","symbol":"CMRA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2023-01-06T16:45:37.000Z","date":"2023-01-04","kind":"purchase","acquired":true,"shares":743243,"price":0.25,"value":185810.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 4, 2023, pursuant to a private placement offering by the Issuer, the Reporting Person acquired 743,243 Units, each Unit consisting of (i) one share of the Issuer's Common Stock and (ii) one Warrant to purchase two shares of Common Stock. The combined purchase price in the Offering was $1.48 per Unit, inclusive of $1.23 per share of Common Stock and $0.25 per Warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 4, 2023, pursuant to a private placement offering by the Issuer, the Reporting Person acquired 743,243 Units, each Unit consisting of (i) one share of the Issuer's Common Stock and (ii) one Warrant to purchase two shares of Common Stock. The combined purchase price in the Offering was $1.48 per Unit, inclusive of $1.23 per share of Common Stock and $0.25 per Warrant."}],"balance_after":743243,"derivative":{"exercise_price":1.23,"exercise_date":"2023-01-04","expiration_date":"2028-01-04","underlying":"Common Stock","underlying_shares":1486486},"source":{"system":"sec-edgar","filing":"0000899243-23-001182","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1448698/000089924323001182/doc4.xml","form_type":"4"}},{"id":2060283,"issuer":{"id":94670,"kind":"organization","name":"Comera Life Sciences Holdings, Inc.","symbol":"CMRA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-01-06T16:45:37.000Z","date":"2023-01-04","kind":"purchase","acquired":true,"shares":743243,"price":1.23,"value":914188.89,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 4, 2023, pursuant to a private placement offering by the Issuer, the Reporting Person acquired 743,243 Units, each Unit consisting of (i) one share of the Issuer's Common Stock and (ii) one Warrant to purchase two shares of Common Stock. The combined purchase price in the Offering was $1.48 per Unit, inclusive of $1.23 per share of Common Stock and $0.25 per Warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 4, 2023, pursuant to a private placement offering by the Issuer, the Reporting Person acquired 743,243 Units, each Unit consisting of (i) one share of the Issuer's Common Stock and (ii) one Warrant to purchase two shares of Common Stock. The combined purchase price in the Offering was $1.48 per Unit, inclusive of $1.23 per share of Common Stock and $0.25 per Warrant."}],"balance_after":2879666,"source":{"system":"sec-edgar","filing":"0000899243-23-001182","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1448698/000089924323001182/doc4.xml","form_type":"4"}},{"id":2095191,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Warrants (right to buy)","published_at":"2022-12-07T02:02:08.000Z","date":"2022-12-02","kind":"purchase","acquired":true,"shares":523512,"price":0.125,"value":65439.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The reporting person entered into a Securities Purchase Agreement with the Issuer on November 23, 2022, pursuant to which, on December 2, 2022, the reporting person acquired an aggregate of 261,756 units for a purchase price of $3.53 per unit, each unit consisting of one share of common stock, par value $0.05 per share (\"Common Stock\"), and two warrants, each exercisable to purchase one share of Common Stock at an exercise price of $3.28 per share. The purchase price for each unit included $0.125 for each warrant in accordance with Nasdaq rules."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person entered into a Securities Purchase Agreement with the Issuer on November 23, 2022, pursuant to which, on December 2, 2022, the reporting person acquired an aggregate of 261,756 units for a purchase price of $3.53 per unit, each unit consisting of one share of common stock, par value $0.05 per share (\"Common Stock\"), and two warrants, each exercisable to purchase one share of Common Stock at an exercise price of $3.28 per share. The purchase price for each unit included $0.125 for each warrant in accordance with Nasdaq rules."}],"balance_after":523512,"derivative":{"exercise_price":3.28,"exercise_date":"2023-06-02","expiration_date":"2028-06-02","underlying":"Common Stock, par value $0.005 per share","underlying_shares":523512},"source":{"system":"sec-edgar","filing":"0001140361-22-044639","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/748592/000114036122044639/form4.xml","form_type":"4"}},{"id":2095190,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2022-12-07T02:02:08.000Z","date":"2022-12-02","kind":"purchase","acquired":true,"shares":261756,"price":3.28,"value":858559.68,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person entered into a Securities Purchase Agreement with the Issuer on November 23, 2022, pursuant to which, on December 2, 2022, the reporting person acquired an aggregate of 261,756 units for a purchase price of $3.53 per unit, each unit consisting of one share of common stock, par value $0.05 per share (\"Common Stock\"), and two warrants, each exercisable to purchase one share of Common Stock at an exercise price of $3.28 per share. The purchase price for each unit included $0.125 for each warrant in accordance with Nasdaq rules."}],"balance_after":556465,"source":{"system":"sec-edgar","filing":"0001140361-22-044639","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/748592/000114036122044639/form4.xml","form_type":"4"}},{"id":2132930,"issuer":{"id":94670,"kind":"organization","name":"Comera Life Sciences Holdings, Inc.","symbol":"CMRA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-10-24T16:03:25.000Z","date":"2022-10-21","kind":"purchase","acquired":true,"shares":11691,"price":1.5937,"value":18631.9467,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price.  These shares were purchased in multiple transactions at prices ranging from $1.46 to $1.65 inclusive.  The report person undertakes to provide to Comera Life Sciences Holdings, Inc. (\"Comera\"), any security holder of Comera, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 2."}],"balance_after":649937,"source":{"system":"sec-edgar","filing":"0001062993-22-021051","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1448698/000106299322021051/form4.xml","form_type":"4"}},{"id":2132929,"issuer":{"id":94670,"kind":"organization","name":"Comera Life Sciences Holdings, Inc.","symbol":"CMRA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-10-24T16:03:25.000Z","date":"2022-10-20","kind":"purchase","acquired":true,"shares":3316,"price":1.5224,"value":5048.2784,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted-average price.  These shares were purchased in multiple transactions at prices ranging from $1.52 to $1.54 inclusive.  The report person undertakes to provide to Comera Life Sciences Holdings, Inc. (\"Comera\"), any security holder of Comera, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 1."}],"balance_after":638246,"source":{"system":"sec-edgar","filing":"0001062993-22-021051","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1448698/000106299322021051/form4.xml","form_type":"4"}},{"id":2135449,"issuer":{"id":94670,"kind":"organization","name":"Comera Life Sciences Holdings, Inc.","symbol":"CMRA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-10-18T16:04:08.000Z","date":"2022-10-17","kind":"purchase","acquired":true,"shares":15266,"price":1.6602,"value":25344.6132,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price.  These shares were purchased in multiple transactions at prices ranging from $1.66 to $1.70 inclusive.  The report person undertakes to provide to Comera Life Sciences Holdings, Inc. (\"Comera\"), any security holder of Comera, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 2."}],"balance_after":634930,"source":{"system":"sec-edgar","filing":"0001062993-22-020905","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1448698/000106299322020905/form4.xml","form_type":"4"}},{"id":2135448,"issuer":{"id":94670,"kind":"organization","name":"Comera Life Sciences Holdings, Inc.","symbol":"CMRA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-10-18T16:04:08.000Z","date":"2022-10-14","kind":"purchase","acquired":true,"shares":4253,"price":1.6042,"value":6822.6626,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted-average price.  These shares were purchased in multiple transactions at prices ranging from $1.56 to $1.64 inclusive.  The report person undertakes to provide to Comera Life Sciences Holdings, Inc. (\"Comera\"), any security holder of Comera, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 1."}],"balance_after":619664,"source":{"system":"sec-edgar","filing":"0001062993-22-020905","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1448698/000106299322020905/form4.xml","form_type":"4"}},{"id":2137016,"issuer":{"id":94670,"kind":"organization","name":"Comera Life Sciences Holdings, Inc.","symbol":"CMRA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-10-14T16:03:17.000Z","date":"2022-10-13","kind":"purchase","acquired":true,"shares":10481,"price":1.6589,"value":17386.9309,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted-average price.  These shares were purchased in multiple transactions at prices ranging from $1.58 to $1.70 inclusive.  The report person undertakes to provide to Comera Life Sciences Holdings, Inc. (\"Comera\"), any security holder of Comera, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 1."}],"balance_after":615411,"source":{"system":"sec-edgar","filing":"0001062993-22-020800","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1448698/000106299322020800/form4.xml","form_type":"4"}},{"id":2148676,"issuer":{"id":94670,"kind":"organization","name":"Comera Life Sciences Holdings, Inc.","symbol":"CMRA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-09-30T16:04:10.000Z","date":"2022-09-29","kind":"purchase","acquired":true,"shares":17900,"price":1.8702,"value":33476.58,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted-average price.  These shares were purchased in multiple transactions at prices ranging from $1.77 to $1.88 inclusive.  The report person undertakes to provide to Comera Life Sciences Holdings, Inc. (\"Comera\"), any security holder of Comera, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 1."}],"balance_after":604930,"source":{"system":"sec-edgar","filing":"0001062993-22-020096","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1448698/000106299322020096/form4.xml","form_type":"4"}},{"id":2149385,"issuer":{"id":94670,"kind":"organization","name":"Comera Life Sciences Holdings, Inc.","symbol":"CMRA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-09-29T16:02:26.000Z","date":"2022-09-27","kind":"purchase","acquired":true,"shares":12000,"price":1.6851,"value":20221.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted-average price.  These shares were purchased in multiple transactions at prices ranging from $1.59 to $1.78 inclusive.  The report person undertakes to provide to Comera Life Sciences Holdings, Inc. (\"Comera\"), any security holder of Comera, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 1."}],"balance_after":587030,"source":{"system":"sec-edgar","filing":"0001062993-22-020051","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1448698/000106299322020051/form4.xml","form_type":"4"}},{"id":2196769,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2022-08-04T00:01:33.000Z","date":"2022-08-01","kind":"grant","acquired":true,"shares":165800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable over two years (subject to continued service), with 1/3 of the shares vesting on the grant date and the remaining shares vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":165800,"derivative":{"exercise_price":0.49,"expiration_date":"2032-08-01","underlying":"Common Stock, par value $0.005 per share","underlying_shares":165800},"source":{"system":"sec-edgar","filing":"0001140361-22-028095","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/748592/000114036122028095/form4.xml","form_type":"4"}},{"id":2196768,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2022-08-04T00:01:33.000Z","date":"2022-08-01","kind":"grant","acquired":true,"shares":215100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable over one year (subject to continued service), with 25% of the shares vesting every three months from the grant date."}],"balance_after":215100,"derivative":{"exercise_price":0.49,"expiration_date":"2032-08-01","underlying":"Common Stock, par value $0.005 per share","underlying_shares":215100},"source":{"system":"sec-edgar","filing":"0001140361-22-028095","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/748592/000114036122028095/form4.xml","form_type":"4"}},{"id":2478293,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":true}}],"security":"Stock Option","published_at":"2021-12-11T02:00:52.000Z","date":"2021-12-08","kind":"grant","acquired":true,"shares":67000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"A total of 22,336 of the shares subject to the option vest and become exercisable as of 12:01 a.m. Eastern time on the date of the issuer's 2022 Annual Meeting of Stockholders and the remaining 44,664 shares vest and become exercisable in equal monthly installments over the following 24 months, subject to continued service through each vesting date."}],"balance_after":67000,"derivative":{"exercise_price":5.94,"expiration_date":"2031-12-07","underlying":"Common Stock","underlying_shares":67000},"source":{"system":"sec-edgar","filing":"0001140361-21-041286","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/748592/000114036121041286/form4.xml","form_type":"4"}},{"id":2478292,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-12-11T02:00:52.000Z","date":"2021-06-01","kind":"other","acquired":true,"shares":92,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a stock dividend declared on shares of the Issuer's Series A Preferred Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a stock dividend declared on shares of the Issuer's Series A Preferred Stock."}],"balance_after":5894193,"source":{"system":"sec-edgar","filing":"0001140361-21-041286","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/748592/000114036121041286/form4.xml","form_type":"4"}},{"id":2662461,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2021-06-21T22:00:24.000Z","date":"2021-06-17","kind":"sale","acquired":false,"shares":2000,"price":16.2974,"value":32594.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.25 to $16.35, inclusive."}],"balance_after":5894101,"source":{"system":"sec-edgar","filing":"0001140361-21-021772","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/748592/000114036121021772/form4.xml","form_type":"4"}},{"id":2662460,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2021-06-21T22:00:24.000Z","date":"2021-06-17","kind":"sale","acquired":false,"shares":198000,"price":15.7435,"value":3117213.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.25 to $16.24, inclusive."}],"balance_after":5896101,"source":{"system":"sec-edgar","filing":"0001140361-21-021772","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/748592/000114036121021772/form4.xml","form_type":"4"}},{"id":2662459,"issuer":{"id":8278,"kind":"organization","name":"Ernexa Therapeutics Inc.","symbol":"ERNA"},"owners":[{"id":66352,"kind":"person","name":"Cherington Charles","position":1,"cik":"0001448698","reported_name":"Cherington Charles","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2021-06-21T22:00:24.000Z","date":"2021-06-16","kind":"sale","acquired":false,"shares":200000,"price":15.7338,"value":3146760.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.53 to $16.11, inclusive."}],"balance_after":6094101,"source":{"system":"sec-edgar","filing":"0001140361-21-021772","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/748592/000114036121021772/form4.xml","form_type":"4"}}]}